Pharmaceutical Properties of a Tinted Formulation of a Biguanide Antiseptic Agent, Olanexidine Gluconate

Olanexidine gluconate-containing preoperative antiseptic (OLG-C) is colorless, which makes it difficult to determine its area of application. To overcome this drawback, we realized a stable orange-tinted antiseptic (OLG-T) by adding new additives to OLG-C and investigated its pharmaceutical properti...

Full description

Saved in:
Bibliographic Details
Published inBiological & pharmaceutical bulletin Vol. 45; no. 2; pp. 220 - 225
Main Authors Nishioka, Hisae, Shiozaki, Mari, Nii, Takuya, Hayashi, Nahoki, Hagi, Akifumi
Format Journal Article
LanguageEnglish
Published Japan The Pharmaceutical Society of Japan 01.02.2022
Japan Science and Technology Agency
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Olanexidine gluconate-containing preoperative antiseptic (OLG-C) is colorless, which makes it difficult to determine its area of application. To overcome this drawback, we realized a stable orange-tinted antiseptic (OLG-T) by adding new additives to OLG-C and investigated its pharmaceutical properties compared with OLG-C and povidone iodine (PVP-I). We evaluated the influence of the additives on the antimicrobial activity and adhesiveness of medical adhesives to OLG-T-applied skin by in vitro time-kill/ex vivo micropig skin assays and a peel test using excised micropig skin, respectively. In the in vitro time-kill assay, the bactericidal/fungicidal activity of OLG-T and OLG-C were equivalent. In the ex vivo micropig skin assay, their fast-acting and persistent bactericidal activities against vancomycin-resistant Enterococcus faecalis were higher than that of PVP-I. In the peel test, the adhesion force of the incise drape and the amount of stripped corneocytes on the peeled drape were comparable between OLG-T- and OLG-C-applied skin, but both were less than those of PVP-I-applied skin. The drapes for OLG-T- and OLG-C-applied skin had moderate adhesion force, and the drape-related injuries were expected to be weak. These results suggest that OLG-T performs no worse than OLG-C in terms of its antimicrobial activity and medical adhesive compatibility. Therefore, we expect OLG-T to lead to more convenient preoperative skin preparation and further contribute to lowering surgical site infection rates.
AbstractList Olanexidine gluconate-containing preoperative antiseptic (OLG-C) is colorless, which makes it difficult to determine its area of application. To overcome this drawback, we realized a stable orange-tinted antiseptic (OLG-T) by adding new additives to OLG-C and investigated its pharmaceutical properties compared with OLG-C and povidone iodine (PVP-I). We evaluated the influence of the additives on the antimicrobial activity and adhesiveness of medical adhesives to OLG-T-applied skin by in vitro time-kill/ex vivo micropig skin assays and a peel test using excised micropig skin, respectively. In the in vitro time-kill assay, the bactericidal/fungicidal activity of OLG-T and OLG-C were equivalent. In the ex vivo micropig skin assay, their fast-acting and persistent bactericidal activities against vancomycin-resistant Enterococcus faecalis were higher than that of PVP-I. In the peel test, the adhesion force of the incise drape and the amount of stripped corneocytes on the peeled drape were comparable between OLG-T- and OLG-C-applied skin, but both were less than those of PVP-I-applied skin. The drapes for OLG-T- and OLG-C-applied skin had moderate adhesion force, and the drape-related injuries were expected to be weak. These results suggest that OLG-T performs no worse than OLG-C in terms of its antimicrobial activity and medical adhesive compatibility. Therefore, we expect OLG-T to lead to more convenient preoperative skin preparation and further contribute to lowering surgical site infection rates.
ArticleNumber b21-00833
Author Hayashi, Nahoki
Hagi, Akifumi
Nii, Takuya
Nishioka, Hisae
Shiozaki, Mari
Author_xml – sequence: 1
  fullname: Nishioka, Hisae
  organization: Naruto Research Institute, Research and Development Center, Otsuka Pharmaceutical Factory, Inc
– sequence: 2
  fullname: Shiozaki, Mari
  organization: Pharmaceutical Technology Department, Technical Center, Otsuka Pharmaceutical Factory, Inc
– sequence: 3
  fullname: Nii, Takuya
  organization: Naruto Research Institute, Research and Development Center, Otsuka Pharmaceutical Factory, Inc
– sequence: 4
  fullname: Hayashi, Nahoki
  organization: Naruto Research Institute, Research and Development Center, Otsuka Pharmaceutical Factory, Inc
– sequence: 5
  fullname: Hagi, Akifumi
  organization: Naruto Research Institute, Research and Development Center, Otsuka Pharmaceutical Factory, Inc
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34819410$$D View this record in MEDLINE/PubMed
BookMark eNpdkT1vFDEQhi0URC6BkhZZoqHIBn_uR3mcSECKlBShtrz27MWnXXuxvRL8e7y55AqasTR-5tVongt05oMHhD5Sck2ZaL_2c3_dM1oR0nL-Bm0oF00lGZVnaEM62lY1le05ukjpQAhpCOPv0DkXLe0EJRv09PCk46QNLNkZPeKHGGaI2UHCYcAaPzqfweKbEKdl1NkFf-x_c_tFe2cBb312CeYyjrd78PkK34_awx9nnQd8Oy4meJ3hPXo76DHBh5f3Ev26-f64-1Hd3d_-3G3vKiMZz5WmZtC90JRS0zRtx9Y6CE5qEIJIO7QDr7vagCGdMW3DeGe1BWst1EY0nF-iL8fcOYbfC6SsJpcMjOtOYUmK1YTVXAq5op__Qw9hib5sVygmGiIpFYWqjpSJIaUIg5qjm3T8qyhRqwJVFKiiQD0rKPynl9Sln8Ce6NebF2B3BA4p6z2cAF3ObkZ4jhNSsbWcYk-_pvhS4Pk_k5Sb7A
Cites_doi 10.1001/jamasurg.2017.0904
10.1111/j.1600-0846.2005.00088.x
10.1007/978-1-4613-0671-9_22
10.1248/cpb.58.1366
10.1007/s00423-020-02007-6
10.1001/archsurg.1985.01390360023006
10.1097/WON.0b013e3182995516
10.1201/9780203909256.ch24
10.1016/j.ajic.2008.12.008
10.1016/j.ajic.2008.12.010
10.1099/jmm.0.000870
10.1016/S1473-3099(20)30281-4
10.1128/AAC.05048-14
10.1007/978-1-60761-594-1_22
10.1016/S1473-3099(20)30225-5
10.1248/bpb.34.555
10.1021/acs.jmedchem.7b00010
10.1016/S0195-6701(08)60017-1
10.1016/j.jhin.2004.06.030
10.1248/bpb.b18-00821
10.1086/501572
10.1021/acsomega.9b03305
10.1016/j.jos.2019.07.008
10.1099/jmm.0.080861-0
10.1128/CMR.14.2.244-269.2001
10.1177/175045891302301104
ContentType Journal Article
Copyright 2022 The Pharmaceutical Society of Japan
Copyright Japan Science and Technology Agency 2022
Copyright_xml – notice: 2022 The Pharmaceutical Society of Japan
– notice: Copyright Japan Science and Technology Agency 2022
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7QR
7TK
7U9
8FD
FR3
H94
P64
7X8
DOI 10.1248/bpb.b21-00833
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList
Virology and AIDS Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1347-5215
EndPage 225
ExternalDocumentID 10_1248_bpb_b21_00833
34819410
article_bpb_45_2_45_b21_00833_article_char_en
Genre Journal Article
GroupedDBID ---
23N
2WC
5GY
6J9
ACGFO
ACIWK
ACPRK
ADBBV
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
HH5
JMI
JSF
JSH
KQ8
MOJWN
OK1
P2P
RJT
RZJ
TR2
XSB
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7QR
7TK
7U9
8FD
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c523t-a1cfab4a111c77892c778f4306e4405df8f3696cec09cc87239dadeddde6c4733
ISSN 0918-6158
IngestDate Thu Apr 11 23:05:00 EDT 2024
Thu Oct 10 19:19:54 EDT 2024
Fri Aug 23 01:03:17 EDT 2024
Thu May 23 23:37:08 EDT 2024
Thu Aug 17 20:30:34 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords antiseptic
persistence
antimicrobial activity
ex vivo skin model
olanexidine
peel test
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c523t-a1cfab4a111c77892c778f4306e4405df8f3696cec09cc87239dadeddde6c4733
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/bpb/45/2/45_b21-00833/_article/-char/en
PMID 34819410
PQID 2624705114
PQPubID 1966364
PageCount 6
ParticipantIDs proquest_miscellaneous_2602635453
proquest_journals_2624705114
crossref_primary_10_1248_bpb_b21_00833
pubmed_primary_34819410
jstage_primary_article_bpb_45_2_45_b21_00833_article_char_en
PublicationCentury 2000
PublicationDate 2022-02-01
PublicationDateYYYYMMDD 2022-02-01
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-01
  day: 01
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Tokyo
PublicationTitle Biological & pharmaceutical bulletin
PublicationTitleAlternate Biol Pharm Bull
PublicationYear 2022
Publisher The Pharmaceutical Society of Japan
Japan Science and Technology Agency
Publisher_xml – name: The Pharmaceutical Society of Japan
– name: Japan Science and Technology Agency
References 18) “ASTM International E 1054-08 (Reapproved 2013). Standard test methods for evaluation of inactivators of antimicrobial agents.”: ‹https://www.astm.org/e1054-08r13.html›, accessed 4 May, 2021.
10) Harihara Y. [Experience with used the olanexidine-containing preoperative skin antiseptic]. Shujyutsu Igaku (Journal of Japanese Association for Operating Room Technology), 41, 16–20 (2020).
25) Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin. Microbiol. Rev., 14, 244–269 (2001).
29) Chow J, Ng J, Pun A. Effects of food colouring added to 2% chlorhexidine gluconate and 70% alcohol for surgical site antisepsis. J. Perioper. Pract., 23, 255–257 (2013).
17) Beausoleil CM. A guide for validation of neutralizer systems used in topical antimicrobial efficacy evaluations. Handbook of topical antimicrobials. (Paulson DS ed.) Marcel Dekker, New York, pp. 365–376 (2003).
4) National Institute for Health and Care Excellence. “Surgical site infections: prevention and treatment. NICE guideline [NG125].” (Last updated 19 August 2020): ‹https://www.nice.org.uk/guidance/ng125›, accessed 28 September, 2021.
6) Inoue Y, Hagi A, Nii T, Tsubotani Y, Nakata H, Iwata K. Novel antiseptic compound OPB-2045G shows potent bactericidal activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus both in vitro and in vivo: a pilot study in animals. J. Med. Microbiol., 64, 32–36 (2015).
20) Gaonkar TA, Geraldo I, Caraos L, Modak SM. An alcohol hand rub containing a synergistic combination of an emollient and preservatives: prolonged activity against transient pathogens. J. Hosp. Infect., 59, 12–18 (2005).
5) Hagi A, Iwata K, Nii T, Nakata H, Tsubotani Y, Inoue Y. Bactericidal effects and mechanism of action of olanexidine gluconate, a new antiseptic. Antimicrob. Agents Chemother., 59, 4551–4559 (2015).
11) Obara H, Takeuchi M, Kawakubo H, Shinoda M, Okabayashi K, Hayashi K, Sekimoto Y, Maeda Y, Kondo T, Sato Y, Kitagawa Y. Aqueous olanexidine versus aqueous povidone-iodine for surgical skin antisepsis on the incidence of surgical site infections after clean-contaminated surgery: a multicentre, prospective, blinded-endpoint, randomised controlled trial. Lancet Infect. Dis., 20, 1281–1289 (2020).
13) Willy C, Vogt D. Should olanexidine be used routinely for surgical skin antisepsis? Lancet Infect. Dis., 20, 1219–1220 (2020).
8) Flick AC, Ding HX, Leverett CA, Kyne RE Jr, Liu KK, Fink SJ, O’Donnell CJ. Synthetic approaches to the new drugs approved during 2015. J. Med. Chem., 60, 6480–6515 (2017).
30) Tokumura F, Umekage K, Sado M, Otsuka S, Suda S, Taniguchi M, Yamori A, Nakamura A, Kawai J, Oka K. Skin irritation due to repetitive application of adhesive tape: the influence of adhesive strength and seasonal variability. Skin Res. Technol., 11, 102–106 (2005).
32) Chen X, Taguchi T. Enhanced skin adhesive property of hydrophobically modified poly(vinyl alcohol) films. ACS Omega, 5, 1519–1527 (2020).
34) Nishiwaki Y, Matsunaga T, Kumasaki M. Study of the hygroscopic deterioration of ammonium perchlorate/magnesium mixture. Sci. Tech. Energetic Materials, 79, 15–21 (2018).  ‹http://www.jes.or.jp/mag/stem/Vol.79/documents/Vol.79,No.1,p.15-21.pdf.›.
15) McNichol L, Lund C, Rosen T, Gray M. Medical adhesives and patient safety: state of the science:consensus statements for the assessment, prevention, and treatment of adhesive-related skin injuries. J. Wound Ostomy Continence Nurs., 40, 365–380, quiz, E1–E2 (2013).
31) Jaffe HL, Rosenblum FM. Poly(vinyl alcohol) for adhesives. Handbook of Adhesives. Springer, Boston, pp. 401–407 (1990).
3) Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, Reinke CE, Morgan S, Solomkin JS, Mazuski JE, Dellinger EP, Itani KMF, Berbari EF, Segreti J, Parvizi J, Blanchard J, Allen G, Kluytmans JAJW, Donlan R, Schecter WP. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg., 152, 784–791 (2017).
23) Nakano Y, Saito K. Quantitative method for evaluating skin irritation caused by medical adhesives. Nitto Technical Report, 28, 50–57 (1990).
9) Asukai M, Ohishi T, Fujita T, Suzuki D, Nishida T, Sugiura K, Matsuyama Y. Olanexidine gluconate versus povidone-iodine for preventing surgical-site infection in orthopaedic surgery: a retrospective study. J. Orthop. Sci., 24, 1125–1129 (2019).
16) “ASTM International E 2315-16. Standard guide for assessment of antimicrobial activity using a time-kill procedure.” ‹https://www.astm.org/e2315-16.html›, accessed 27 December, 2016.
19) Kaiser N, Klein D, Karanja P, Greten Z, Newman J. Inactivation of chlorhexidine gluconate on skin by incompatible alcohol hand sanitizing gels. Am. J. Infect. Control, 37, 569–573 (2009).
21) Rubinchik E, Pasetka C. Ex vivo skin infection model. Methods Mol. Biol., 618, 359–369 (2010).
1) Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990 s: attributable mortality, excess length of hospitalization, and extra costs. Infect. Control Hosp. Epidemiol., 20, 725–730 (1999).
33) Xiang C, Wang Y, Zhan X, Luo L, Li L, Li C. Calculating critical relative humidity from solubility according to Pitzer ion interaction model. Chem. Pharm. Bull., 58, 1366–1368 (2010).
2) de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am. J. Infect. Control, 37, 387–397 (2009).
24) The Ministry of Health. Labour and Welfare. Methods of adhesion testing. The Japanese Pharmacopoeia Seventeenth Edition. The Ministry of Health, Labour and Welfare, Tokyo, pp. 161–163 (2016).: ‹https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/JP17_REV_1.pdf›, accessed 28 September, 2021.
14) Alexander JW, Aerni S, Plettner JP. Development of a safe and effective one-minute preoperative skin preparation. Arch. Surg., 120, 1357–1361 (1985).
7) Seyama S, Nishioka H, Nakaminami H, Nakase K, Wajima T, Hagi A, Noguchi N. Evaluation of in vitro bactericidal activity of 1.5% olanexidine gluconate, a novel biguanide antiseptic agent. Biol. Pharm. Bull., 42, 512–515 (2019).
12) Yamamoto M, Hara K, Sugezawa K, Uejima C, Tanio A, Tada Y, Shishido Y, Miyatani K, Hanaki T, Kihara K, Matsunaga T, Tokuyasu N, Takano S, Sakamoto T, Honjo S, Fujiwara Y. Disinfection with single or double usage of new antiseptic olanexidine gluconate in general surgery: a randomized study. Langenbecks Arch. Surg., 405, 1183–1189 (2020).
28) Takeuchi H, Terasaka S, Sakurai T, Furuya A, Urano H, Sugibayashi K. Variation assessment for in vitro permeabilities through Yucatan micropig skin. Biol. Pharm. Bull., 34, 555–561 (2011).
22) Nishioka H, Nagahama A, Inoue Y, Hagi A. Evaluation of fast-acting bactericidal activity and substantivity of an antiseptic agent, olanexidine gluconate, using an ex vivo skin model. J. Med. Microbiol., 67, 1796–1803 (2018).
26) Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J. Hosp. Infect., 70 (Suppl. 2), 3–10 (2008).
27) Lavker RM, Dong G, Zheng PS, Murphy GF. Hairless micropig skin. A novel model for studies of cutaneous biology. Am. J. Pathol., 138, 687–697 (1991).
22
23
24
25
26
27
28
29
30
31
10
32
11
33
12
34
13
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
20
21
References_xml – ident: 3
  doi: 10.1001/jamasurg.2017.0904
– ident: 18
– ident: 4
– ident: 30
  doi: 10.1111/j.1600-0846.2005.00088.x
– ident: 31
  doi: 10.1007/978-1-4613-0671-9_22
– ident: 33
  doi: 10.1248/cpb.58.1366
– ident: 12
  doi: 10.1007/s00423-020-02007-6
– ident: 10
– ident: 14
  doi: 10.1001/archsurg.1985.01390360023006
– ident: 16
– ident: 15
  doi: 10.1097/WON.0b013e3182995516
– ident: 17
  doi: 10.1201/9780203909256.ch24
– ident: 19
  doi: 10.1016/j.ajic.2008.12.008
– ident: 2
  doi: 10.1016/j.ajic.2008.12.010
– ident: 24
– ident: 22
  doi: 10.1099/jmm.0.000870
– ident: 13
  doi: 10.1016/S1473-3099(20)30281-4
– ident: 5
  doi: 10.1128/AAC.05048-14
– ident: 21
  doi: 10.1007/978-1-60761-594-1_22
– ident: 11
  doi: 10.1016/S1473-3099(20)30225-5
– ident: 28
  doi: 10.1248/bpb.34.555
– ident: 8
  doi: 10.1021/acs.jmedchem.7b00010
– ident: 26
  doi: 10.1016/S0195-6701(08)60017-1
– ident: 20
  doi: 10.1016/j.jhin.2004.06.030
– ident: 34
– ident: 7
  doi: 10.1248/bpb.b18-00821
– ident: 1
  doi: 10.1086/501572
– ident: 32
  doi: 10.1021/acsomega.9b03305
– ident: 9
  doi: 10.1016/j.jos.2019.07.008
– ident: 6
  doi: 10.1099/jmm.0.080861-0
– ident: 25
  doi: 10.1128/CMR.14.2.244-269.2001
– ident: 29
  doi: 10.1177/175045891302301104
– ident: 27
– ident: 23
SSID ssj0007023
Score 2.3910809
Snippet Olanexidine gluconate-containing preoperative antiseptic (OLG-C) is colorless, which makes it difficult to determine its area of application. To overcome this...
SourceID proquest
crossref
pubmed
jstage
SourceType Aggregation Database
Index Database
Publisher
StartPage 220
SubjectTerms Adhesiveness
Animals
Anti-Infective Agents, Local - administration & dosage
Antimicrobial activity
Antimicrobial agents
antiseptic
Azo Compounds - administration & dosage
Bacteria - drug effects
Bacteria - growth & development
Biguanides - administration & dosage
Drug Compounding
ex vivo skin model
Female
Food Coloring Agents - administration & dosage
Fungicidal activity
Glucuronates - administration & dosage
Iodine
olanexidine
peel test
persistence
Povidone
Skin - drug effects
Skin - microbiology
Skin tests
Surgical site infections
Swine
Vancomycin
Title Pharmaceutical Properties of a Tinted Formulation of a Biguanide Antiseptic Agent, Olanexidine Gluconate
URI https://www.jstage.jst.go.jp/article/bpb/45/2/45_b21-00833/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/34819410
https://www.proquest.com/docview/2624705114
https://search.proquest.com/docview/2602635453
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Biological and Pharmaceutical Bulletin, 2022/02/01, Vol.45(2), pp.220-225
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKQLAXBB0fhYGMhPpCM5rETWKJlzIxKiRgEp20t8h2kjVUS6q1lej457mzEycRTAJerMp2Giu_X8538X0Q8tqdqCDgPnekkGCgRKHvRBI9pyKMynSRBNrb4kswO2Ofzifnvd7PdnTJRh6p6z_GlfwPqtAHuGKU7D8ga_8UOuA34AstIAztX2F8uuh8kD7FD-tXmCHVRD3OMRdE8uYE1NKqSJfpf59fbEWRJ5iSBGsxrzBp6xRjrPCBf0X31x95gurnR3RoL8Sm4y9kylfqOyJvVt1FyHY-b3PgscjLpdZRZ_laWCJ9g-5rYapmfwaLvblAd83FcrsTjYDcYdUnsx8symXe_loBhu7Yen6kRsL6LATr18Rw1iLYZJSsqOa15amOlPtdznsMYxfkSh5Jz3VQj_Tb8wCm1aUGHeOMOas8Z7uJteuhW-S2B1Iq0lK9sZ1C0GaqpKxwt7ede-2Tu_XVHX3mzndQ6S_Sm60VrbXMH5D7lblBp4Y7D0kvLfrkYAqQlpc7OqTaAVifrPTJveO6-F-fDCtq7UZ03kTorUf6EpvsfHdAFl0O0oaDtMyooIaDtMVB0285SBsOUs3BEW0xkFoGPiJnJx_mxzOnqt7hqInnbxzhqkxIJuCFV2EYcQ_bjIGJmjKwEpIsyrCWpErVmCsVhZ7PE5GkCey3gWKh7z8me0VZpE8JFT7sPJmruAvGShAlkqcZZ-OQhyCCuBIDMqwxiFcmSUuMxi3gFgNuMeAWa9wG5J1ByE6r3l09jU1iDxs73Y5iBCQInAE5rHGNKzGwjr3AYyFsbS4bkFd2GODCkzd4XOUW54wx6RObwAqeGD7YFdREenbjyHOy37xKh2Rvc7VNX4AqvJEvNWV_AdAMtlc
link.rule.ids 315,783,787,27938,27939
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmaceutical+Properties+of+a+Tinted+Formulation+of+a+Biguanide+Antiseptic+Agent%2C+Olanexidine+Gluconate&rft.jtitle=Biological+%26+pharmaceutical+bulletin&rft.au=Nishioka%2C+Hisae&rft.au=Shiozaki%2C+Mari&rft.au=Nii%2C+Takuya&rft.au=Hayashi%2C+Nahoki&rft.date=2022-02-01&rft.eissn=1347-5215&rft.volume=45&rft.issue=2&rft.spage=220&rft_id=info:doi/10.1248%2Fbpb.b21-00833&rft_id=info%3Apmid%2F34819410&rft.externalDocID=34819410
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon